{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:20:43Z","timestamp":1756383643381},"reference-count":14,"publisher":"BMJ","license":[{"start":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:00:00Z","timestamp":1581984000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"DOI":"10.1136\/bmj.m579","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T16:04:54Z","timestamp":1582041894000},"page":"m579","update-policy":"http:\/\/dx.doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["UK deal over inclisiran"],"prefix":"10.1136","author":[{"given":"Paula","family":"Byrne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Cullinan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Mintzes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan M","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,2,18]]},"reference":[{"key":"key20200223000050_ref1","unstructured":"New heart disease drug to be made available for NHS patients. Press release, 13 Jan 2020. https:\/\/www.gov.uk\/government\/news\/new-heart-disease-drug-to-be-made-available-for-nhs-patients."},{"key":"key20200223000050_ref2","unstructured":"Sagonowsky E. JPM: Novartis teams up with NHS in \u2018world-first\u2019 access deal for PCSK9 hopeful inclisiran. Fierce Pharma, 13 Jan 2020. https:\/\/www.fiercepharma.com\/pharma\/novartis-teams-up-nhs-england-world-first-access-agreement-for-inclisiran."},{"key":"key20200223000050_ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l5674"},{"key":"key20200223000050_ref4","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006910"},{"key":"key20200223000050_ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1614154"},{"key":"key20200223000050_ref6","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2019.0835"},{"key":"key20200223000050_ref7","unstructured":"European Society of Cardiology. Substantial LDL-C reductions with the siRNA, inclisiran: results from ORION 11. Press release, 4 Sep 2019. https:\/\/www.escardio.org\/Congresses-&-Events\/ESC-Congress\/Congress-resources\/Congress-news\/substantial-ldlc-reductions-with-the-sirna-inclisiran-results-from-orion11."},{"key":"key20200223000050_ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.7242"},{"key":"key20200223000050_ref9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009753.pub2"},{"key":"key20200223000050_ref10","unstructured":"ClinicalTrials.gov. Inclisiran for subjects with ACSVD or ACSVD-risk equivalents and elevated low-density lipoprotein cholesterol (ORION-11). (Accessed 13 Feb 2020.) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03400800"},{"key":"key20200223000050_ref11","unstructured":"Novartis. Annual report 2018. 2018. https:\/\/www.novartis.com\/sites\/www.novartis.com\/files\/novartis-annual-report-2018-en.pdf."},{"key":"key20200223000050_ref12","unstructured":"Pharmaceutical Research and Manufacturers of America. Medicines in development for heart disease and stroke 2018 drug list. 2018. https:\/\/www.phrma.org\/Report\/Medicines-in-Development-for-Heart-Disease-and-Stroke-2018-Drug-List."},{"key":"key20200223000050_ref13","unstructured":"Clinical Trial Service Unit. New heart disease drug to be made available to NHS patients through ground-breaking collaboration. 2020. https:\/\/www.ctsu.ox.ac.uk\/news\/new-heart-disease-drug-to-be-made-available-to-nhs-patients-through-ground-breaking-collaboration."},{"key":"key20200223000050_ref14","unstructured":"Prescription Medicines Code of Practice Authority. Code of practice for the pharmaceutical industry. 2019. https:\/\/www.abpi.org.uk\/media\/6655\/abpi-code-of-practice-2019.pdf."}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.m579","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.m579","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T04:12:02Z","timestamp":1601093522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.m579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,18]]},"references-count":14,"alternative-id":["10.1136\/bmj.m579"],"URL":"https:\/\/doi.org\/10.1136\/bmj.m579","relation":{},"ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,18]]}}}